Concert Pharmaceuticals
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company's approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert's pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.
Last updated on
About Concert Pharmaceuticals
Founded
2006Estimated Revenue
$0-$1MEmployees
11-50Funding / Mkt. Cap
$271MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
PharmaceuticalsSIC Code
28NAICs Code
3254Location
City
LexingtonState
MassachusettsCountry
United StatesConcert Pharmaceuticals
Find your buyer within Concert Pharmaceuticals